Hyperthyroidism controlled by administration of blocking and replacement therapy before inpatient radioisotope therapy for the patient of Graves' disease

Hyperthyroidism controlled by administration of blocking and replacement therapy before inpatient radioisotope therapy for the patient of Graves' disease - Thyroid function control in Graves' disease during 131I therapy

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000022261

Enrollment

Registered

2016-05-18

Start date

2014-04-23

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Graves&#39

Interventions

Intervention: the blocking and replacement therapy (BRT) group (BR group), which received twice the amount of previously given ATD and LT4 replacement starting 2 or more months prior to RIT. Control:

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: i) deemed difficult to achieve remission with ATD treatment; ii) patient requested RIT; iii) estimated thyroid gland volume of 80 ml or greater

Exclusion criteria

Exclusion criteria: Inorganic iodine administered in combination, poorly controlled cardiac disease, diabetes, kidney disease, severe liver disease, and active ocular disease. However, patients with concomitant controlled cardiac diseases and diabetes were treated in the BR group.

Design outcomes

Primary

Measure	Time frame
Free thyroxine (FT4) and free triiodothyronine (FT3) levels during RIT	—

Countries

Japan

Contacts

Public ContactMiho Suzuki

Ito Hospital Internal medicine

miho-suzuki@ito-hospital.jp03-3402-7411

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026

Hyperthyroidism controlled by administration of blocking and replacement therapy before inpatient radioisotope therapy for the patient of Graves&#39; disease